BioCentury
ARTICLE | Company News

Abbott gets rights to Takeda's Actos

March 7, 2000 8:00 AM UTC

ABT received exclusive marketing rights in Latin America to Actos pioglitazone, a thiazolidinedione insulin-sensitizing agent to treat Type II diabetes, developed by Takeda (Osaka, Japan). ABT expects...